Global Tuberculosis Therapeutics Market is expected to grow at an impressive rate during the forecast period on account of the growing need to find new therapeutic solutions to combat the spread of tuberculosis and improve patient outcomes. Tuberculosis (TB) is a highly infectious and potentially fatal disease caused by the bacteria Mycobacterium tuberculosis. It primarily affects the lungs but can also target other parts of the body, including the brain, kidneys, and spine. According to the World Health Organization (WHO), TB is one of the top 10 causes of death worldwide, with an estimated 10 million people falling ill with the disease in 2019. With such a high incidence rate, the demand for tuberculosis therapeutics is expected to continue to rise, thereby driving the growth of global tuberculosis therapeutics market during the forecast period.

Tuberculosis is a global health issue that affects people of all ages and from all walks of life. Despite the availability of effective treatments, the disease continues to be a major public health concern, particularly in low and middle-income countries. According to the WHO, over 90% of TB cases occur in developing countries, where access to proper healthcare and diagnostic tools is limited. As a result, there is an urgent need for effective, affordable, and accessible TB therapeutics to address the global burden of the disease. This in turn is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Additionally, global population is aging, and older adults are more susceptible to TB due to age-related declines in immune function. As the population continues to age, the demand for TB therapeutics that are safe and effective in older adults is expected to increase, thereby driving the growth of global tuberculosis therapeutics market.

Increasing Instances of Drug Resistance

Tuberculosis is caused by a bacterium that can mutate rapidly, leading to drug-resistant strains that are difficult to treat. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are two forms of drug-resistant TB that pose a significant challenge to global health. The emergence of drug-resistant strains of TB has increased the demand for novel TB therapeutics that can effectively treat these difficult-to-treat strains. This in turn is expected to increase the demand for novel therapeutics that can address the issue of drug resistance related to tuberculosis, thereby fuelling the growth of global tuberculosis therapeutics market in the coming years. In the past decade, several new TB drugs have been developed, including bedaquiline, delamanid, and pretomanid. Bedaquiline is a novel drug that has been shown to be effective against drug-resistant TB, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Delamanid has also been shown to be effective against drug-resistant TB, particularly when used in combination with other TB drugs. Pretomanid, the newest of the three drugs, has been approved for the treatment of extensively drug-resistant TB.

Advancements in Tuberculosis Diagnostics

Advances in diagnostic tools have also improved the treatment of TB. One example is the use of Xpert MTB/RIF, a rapid molecular diagnostic test that can detect TB and drug resistance in just two hours. Another diagnostic tool is the GeneXpert Omni, which can detect TB and drug resistance in less than 90 minutes. These tools can help clinicians make more accurate diagnoses and choose the most appropriate treatment regimen for their patients. The development in diagnostic methods for tuberculosis is leading to the development of effective therapeutic solutions as well, thereby opening new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Use of Combination Therapies

The use of combination therapies in the treatment of various chronic and infectious diseases has increased over the years significantly opening new opportunities for the growth and development of novel therapeutics. The use of combination therapies is becoming increasingly common in the treatment of TB. Combination therapies involve the use of multiple drugs to treat TB, which can improve treatment outcomes and reduce the risk of drug resistance. One example of a combination therapy is the use of bedaquiline and delamanid in the treatment of MDR-TB. Another combination therapy, called the BPaMZ regimen, uses the drugs bedaquiline, pretomanid, moxifloxacin, and pyrazinamide to treat drug-sensitive TB. The use of combination therapies in the treatment of tuberculosis is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Increased Research and Development Activities

In recent years, there has been a renewed focus on TB research and development. This has led to the discovery of new drugs and therapies that have the potential to improve treatment outcomes for patients with TB. The increased focus on TB research and development has also increased the demand for new and innovative TB therapeutics. According to clinicaltrials.gov, there are around 1,092 studies in different phases of development across the globe for developing a treatment for combating tuberculosis.

Additionally, studies are going on to find effective treatments with shorter regimens. Traditionally, TB treatment has involved a long course of antibiotics that can last for up to two years. However, recent research has shown that shorter treatment regimens may be just as effective. One example is the use of the BPaL regimen, which uses the drugs bedaquiline, pretomanid, and linezolid to treat drug-resistant TB. This regimen has been shown to be effective in treating TB in as little as six months. This in turn is expected to support the growth of global tuberculosis therapeutics market in the coming years.

In addition to these new drugs and regimens, researchers are also exploring the potential of repurposing existing drugs for the treatment of TB. For example, a study published in the journal Science in 2020 found that a drug called niclosamide, which is currently used to treat intestinal infections, showed promising results in killing Mycobacterium tuberculosis in laboratory experiments. The researchers are now planning to conduct clinical trials to test niclosamide's effectiveness in treating TB in humans. This is further expected to open new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Growing Prevalence of HIV

HIV is a virus that attacks cells which help the body fight any kind of infection making the patient suffering from HIV more vulnerable to other diseases and infections. According to WHO, as of 2021, there are around 38.4 million people living with HIV worldwide. People who are infected with HIV are at a much higher risk of developing TB due to their weakened immune systems. According to the WHO, around 8% of all TB cases are HIV-positive. The high prevalence of TB/HIV co-infection has increased the demand for TB therapeutics that can effectively treat both diseases, thereby supporting the growth of global tuberculosis therapeutics market.



Download Free Sample Report


Market Segmentation

Global Tuberculosis Therapeutics Market can be segmented by disease type, by therapy, by route of administration, by dosage form, by distribution channel, and by region. Based on disease type, global tuberculosis therapeutics market can be split into active tuberculosis and latent tuberculosis. By therapy, the global tuberculosis therapeutics market can be divided into first line therapy and second line therapy. Based on route of administration, the global tuberculosis therapeutics can be categorized into oral, parenteral, and others. By dosage form, the global tuberculosis therapeutics market can be segmented into tablets, capsules, injection, and others. In terms of distribution channel, the global tuberculosis therapeutics market can be grouped into hospital pharmacy, retail pharmacy, and online pharmacy. Regionally, the global tuberculosis therapeutics market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

 

Market Players

AstraZeneca, Plc., Johnson & Johnson, Eli Lilly And Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., among others are some of the leading players operating in the global Tuberculosis Therapeutics market.

Recent Developments

In 2019, Otsuka Pharmaceutical Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for a new TB drug, Pretomanid, for the treatment of extensively drug-resistant TB.

GlaxoSmithKline (GSK), which has a TB drug development program focused on developing drugs that are effective against drug-resistant TB. GSK is currently testing a drug called GSK3036656 in clinical trials, which has shown promise in early studies.

In 2019, the US Food and Drug Administration (FDA) approved a new drug called pretomanid. Pretomanid is part of a three-drug regimen called BPaL, which also includes bedaquiline and linezolid, that has been shown to be highly effective in treating highly drug-resistant forms of TB. In a phase III trial conducted in South Africa, the BPaL regimen cured 90% of patients with extensively drug-resistant TB, a form of TB that is resistant to at least four of the main TB drugs. The BPaL regimen is also shorter than the previous standard of care for drug-resistant TB, taking just six months instead of up to two years.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

By Disease Type

By Therapy

By Route of Administration

By Dosage Form

By Distribution Channel

By Region

Regional scope

North America, Europe, Asia Pacific, South America, Middle East & Africa

Key companies profiled

AstraZeneca, Plc., Johnson & Johnson, Eli Lilly And Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, Global Tuberculosis Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Tuberculosis Therapeutics Market, By Disease Type:

o      Active Tuberculosis

o      Latent Tuberculosis

       ·         Tuberculosis Therapeutics Market, By Therapy:

o      First Line Therapy

o      Second Line Therapy

       ·         Tuberculosis Therapeutics Market, By Route of Administration:

o      Oral

o      Parenteral

o      Others

       ·         Tuberculosis Therapeutics Market, By Therapy:

o      First Line Therapy

o      Second Line Therapy

       ·         Tuberculosis Therapeutics Market, By Region:

o      North America

o   United States

o   Canada

o   Mexico

o      Europe

o   France

o   Germany

o   United Kingdom

o   Italy

o   Spain

o      Asia Pacific

o   China

o   India

o   Japan

o   South Korea

o   Australia

o      South America

o   Brazil

o   Argentina

o   Colombia

o      Middle East & Africa

o   South Africa

o   Saudi Arabia

o   UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Tuberculosis Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Tuberculosis Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validations

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Tuberculosis Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Disease Type (Active Tuberculosis, Latent Tuberculosis)

5.2.2.     By Therapy (First Line Therapy, Second Line Therapy)

5.2.3.     By Route of Administration (Oral, Parenteral, Others)

5.2.4.     By Dosage Form (Tablets, Capsules, Injection, Others)

5.2.5.     By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

5.2.6.     By Region

5.2.7.     By Company (2022)

5.3.  Product Map

5.3.1.     By Disease Type

5.3.2.     By Therapy

5.3.3.     By Route of Administration

5.3.4.     By Dosage Form

5.3.5.     By Distribution Channel

5.3.6.     By Region

6.    North America Tuberculosis Therapeutics Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Disease Type

6.2.2.     By Therapy

6.2.3.     By Route of Administration

6.2.4.     By Dosage Form

6.2.5.     By Distribution Channel

6.2.6.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Tuberculosis Therapeutics Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Disease Type

6.3.1.2.2.             By Therapy

6.3.1.2.3.             By Route of Administration

6.3.1.2.4.             By Dosage Form

6.3.1.2.5.             By Distribution Channel

6.3.2.     Canada Tuberculosis Therapeutics Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Disease Type

6.3.2.2.2.             By Therapy

6.3.2.2.3.             By Route of Administration

6.3.2.2.4.             By Dosage Form

6.3.2.2.5.             By Distribution Channel

6.3.3.     Mexico Tuberculosis Therapeutics Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Disease Type

6.3.3.2.2.             By Therapy

6.3.3.2.3.             By Route of Administration

6.3.3.2.4.             By Dosage Form

6.3.3.2.5.             By Distribution Channel

7.    Europe Tuberculosis Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Disease Type

7.2.2.     By Therapy

7.2.3.     By Route of Administration

7.2.4.     By Dosage Form

7.2.5.     By Distribution Channel

7.2.6.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Tuberculosis Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Disease Type

7.3.1.2.2.             By Therapy

7.3.1.2.3.             By Route of Administration

7.3.1.2.4.             By Dosage Form

7.3.1.2.5.             By Distribution Channel

7.3.2.     Germany Tuberculosis Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Disease Type

7.3.2.2.2.             By Therapy

7.3.2.2.3.             By Route of Administration

7.3.2.2.4.             By Dosage Form

7.3.2.2.5.             By Distribution Channel

7.3.3.     United Kingdom Tuberculosis Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecasty

7.3.3.2.1.             By Disease Type

7.3.3.2.2.             By Therapy

7.3.3.2.3.             By Route of Administration

7.3.3.2.4.             By Dosage Form

7.3.3.2.5.             By Distribution Channel

7.3.4.     Italy Tuberculosis Therapeutics Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Disease Type

7.3.4.2.2.             By Therapy

7.3.4.2.3.             By Route of Administration

7.3.4.2.4.             By Dosage Form

7.3.4.2.5.             By Distribution Channel

7.3.5.     Spain Tuberculosis Therapeutics Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Disease Type

7.3.5.2.2.             By Therapy

7.3.5.2.3.             By Route of Administration

7.3.5.2.4.             By Dosage Form

7.3.5.2.5.             By Distribution Channel

8.    Asia-Pacific Tuberculosis Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Disease Type

8.2.2.     By Therapy

8.2.3.     By Route of Administration

8.2.4.     By Dosage Form

8.2.5.     By Distribution Channel

8.2.6.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Tuberculosis Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Disease Type

8.3.1.2.2.             By Therapy